NeuroVive Pharmaceutical AB (publ): report from EGM

Today, 17 January 2019, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”). A summary of the resolutions follows. All resolutions were unanimous.

Approval of resolution to issue shares with preferential rights for existing shareholders

The Extraordinary General Meeting resolved to approve the Board of Directors’ resolution on 10 December 2018 to increase the company’s share capital by not more than SEK 4,584,853.80 by a rights issue of not more than 91,697,076 shares with preferential rights for existing shareholders.

The right to subscribe for shares in the rights issue shall apply to persons whom on the record date for the rights issue are registered as shareholders in the company. One (1) existing share entitles to one (1) subscription right and one (1) subscription right entitles to subscription of one (1) new share. The record date for determining which shareholders whom are entitled to subscribe for shares with preferential right shall be Monday 21 January 2019. Subscription of shares with subscription rights shall be made through payment in cash during the period from and including 23 January 2019 up to and including 6 February 2019. The Board of Directors shall have the right to extend the subscription and payment period. Notification of interest to subscribe for shares without subscription rights is possible during the subscription period. The subscription price per share is SEK 1.35.

Upon full subscription of the rights issue, the Company will raise approximately SEK 123.8 million before issuance costs.

Resolution to amend the articles of association

The Extraordinary General Meeting also resolved to amend the limits of the share capital in the articles of association from minimum SEK 2,500,000 and maximum SEK 10,000,000 to minimum SEK 4,500,000 and maximum SEK 18,000,000, and to amend the limits of the number of shares in the articles of association from minimum 50,000,000 and maximum 200,000,000 to minimum 90,000,000 and maximum 360,000,000.

The information was submitted for publication, through the agency of the contact person set out below, at 3.00 p.m. CET on 17 January 2019.

For more information please contact:
Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21,

NeuroVive Pharmaceutical AB (publ)  
Medicon Village, 223 81 Lund, Sweden 
Tel: +46 (0)46 275 62 20 (switchboard),
For news subscription, please visit

About NeuroVive 
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio also consists of projects for genetic mitochondrial disorders, cancer and NASH. The company advances drugs for rare diseases through clinical development into the market. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).